LBLee Baker

Lee Baker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lee Baker has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RNA sequencing significantly improves HYDIN diagnosis and defines the effects of common deletions in primary ciliary dyskinesia

    by Carolina Jaramillo Oquendo, Janice Coles, Lee Baker, David J. Bunyan, N. Simon Thomas, James Thompson, Gemma Fryatt, Sajida Khan, David Hunt, John W. Holloway, et al.

    Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder affecting ~1:7500 individuals characterised by recurrent chronic respiratory infections, bronchiectasis, laterality defects, and infertility. While at least 60 PCD-causing genes are reported, approximately 30% of patients remain without a confirmed molecular diagnosis. PCD caused by biallelic HYDIN variants is difficult to diagnose due to a 98% homologous pseudogene ( HYDIN2 ). Additionally, functional ciliary diagnostic testing can be inconclusive due to the lack of discernible HYDIN ciliary ultrastructure defects by electron microscopy. Our aim was to diagnose genetically unresolved PCD patients with strong clinical suspicion of HYDIN defects using RNA sequencing (RNA-seq). RNA-seq was performed on total RNA extracted from patients’ nasal epithelium cultured for 21 days at the air-liquid interface. Splicing abnormalities were detected using rMATS and genome-aligned reads were manually inspected using Integrative Genome Viewer. Thirteen individuals had strong clinical suspicion of PCD, normal TEM and inconclusive genetics: 11/13 had a single pathogenic or likely pathogenic variant in HYDIN , 1/13 had no variants, and 1/13 required clarification of variant origin ( HYDIN vs HYDIN2 ). RNA-seq resolved 11/13 (85%) of cases. The same complex pathogenic aberrant splicing events were seen in seven unrelated patients. This abnormal splice pattern was caused by a large 10-kilobase deletion spanning intron 17 to intron 18. RNA-seq increases the diagnostic yield for patients with suspected PCD and has exposed a HYDIN ‘hotspot’ variant, increasing the observed prevalence of HYDIN -related cases within our genetically diagnosed cohort. Routine PCD genomics testing will now incorporate investigation of this genetic region of HYDIN .

  • Open Access

    Uplift of genetic diagnosis of rare respiratory disease using airway epithelium transcriptome analysis

    by Jelmer Legebeke, Gabrielle Wheway, Lee Baker, Htoo A Wai, Woolf T Walker, N Simon Thomas, Janice Coles, Claire L Jackson, John W Holloway, Jane S Lucas, et al.

    Rare genetic respiratory disease has an incidence rate of more than 1:2500 live births in Northern Europe and carries significant disease burden. Early diagnosis improves outcomes, but many individuals remain without a confident genetic diagnosis. Improved and expanded molecular testing methods are required to improve genetic diagnosis rates and thereby improve clinical outcomes. Using primary ciliary dyskinesia (PCD) as an exemplar rare genetic respiratory disease, we developed a standardized method to identify pathogenic variants using whole transcriptome RNA-sequencing (RNA-seq) of nasal epithelial cells cultured at air-liquid interface (ALI). The method was optimized using cells from healthy volunteers, and people with rhino-pulmonary disease but no diagnostic indication of PCD. We validated the method using nasal epithelial cells from PCD patients with known genetic cause. We then assessed the ability of RNA-seq to identify pathogenic variants and the disease mechanism in PCD likely patients but in whom DNA genetic testing was inconclusive. The majority of 49 targeted PCD genes were optimally identified in RNA-seq data from nasal epithelial cells grown for 21 days at ALI culture. Four PCD-likely patients without a previous genetic diagnosis received a confirmed genetic diagnosis from the findings of the RNA-seq data. We demonstrate the clinical potential of RNA-seq of nasal epithelial cells to identify variants in individuals with genetically unsolved PCD. This uplifted genetic diagnosis should improve genetic counselling, enables family cascade screening, opens the door to potential personalised treatment and care approaches. This methodology could be implemented in other rare lung diseases such as cystic fibrosis.